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Background:  Nicardipine has been used as an effective treatment for acute hypertension. However its safety in patients with low ejection 
fraction (EF) has not been well characterized. We aim to compare the acute effects of nicardipine infusion in patients with depressed and 
normal EF.
methods:  Retrospective case control study compared patients with low EF (<50%) and normal EF (>50%) after intravenous nicardipine. 
Primary outcome included new signs (JVD, crackles, edema) or symptoms (dyspnea, orthopnea) of heart failure (HF), hypotension and 
worsening EF in during 24-48 hours post nicardipine infusion.
results:  A total of 44 patients with low EF and 72 patients with normal EF were included. There were no differences in the composite 
of any new signs of HF nor in the scores measuring new signs and new symptoms or HF (Table 1). There was a higher frequency of 
asymptomatic hypotension (27.9 vs 9%, p = 0.011) in the low EF group. There was a significant improvement in EF after the drip in patients 
with baseline low EF (5.93 ± 1.9 vs -2.15 ± 1.46, p = 0.001). These findings remained consistent after multivariate analysis to control for 
age, gender, total amount of nicardipine, infusion setting (Operating room or Intensive Care) and diabetes.
conclusion:  Nicardipine appears to improve EF in patients with systolic dysfunction without a concomitant worsening in clinical findings of 
HF except for higher rates of asymptomatic hypotension. Further prospective studies are warranted.
Table 1. Baseline Parameter and Outcomes of Interest
Parameter Measured EF<50% EF>50% P value
Baseline Parameters EF (%, mean ± SEM) 33.78 ± 2.45 63.42 ± 0.92 0.00001
Age at presentation in years (mean ± SEM) 69.81 ± 3.24 67.47 ± 1.8 0.818
Gender (% of male patients) 69 62.5 0.49
Cumulative nicardipine dose in mg (mean ± SEM) 54.76 ± 21.48 39.79 ± 9.52 0.565
Outcomes of interest Asymptomatic Hypotension (%) 27.9 9.7 0.011
Composite of any new HF signs (%) 20.5 12.5 0.251
Score of New HF signs in physical exam (mean ± SEM) 2.0 ± 0.62 1.4 ± 0.46 0.39
Score of New HF Symptoms (mean ± SEM) 1.0 ± 0.55 0.14 ± 0.14 0.14
